Virginia Biosciences Commercialization Center (VBCC)
Phase 1 - Safety & dosing Trial for Pancreatic Cancer Therapy — US partner. Israeli partner: BioCancell Therapeutics Ltd. (Jerusalem (Jerusalem Region)). Sector: Life Sciences, Biotechnology. BioCancell teamed with Virginia Bioscience Commercialization Center (VBCC) to conduct Phase I & II clinical trials of its lead drug-candidate, BC-819 as a treatment for pancreatic cancer. Eventually the trial took place at the University of Maryland Medical Center in Baltimore, MD, and Hadassah, Sheba, Hillel Yafeh and Meir Medical Centers in Israel. The outcome of this project received FDA approval after the completion of the clinical trials